the patient must have consented to participate and must have signed and dated an appropriate irb-approved consent form that conforms to federal and institutional guidelines for the ma.32.f study before being enrolled.

the patient must be female.

the patient must reside in the united states or canada.

the patient must be english-speaking.

the patient must be eligible for randomization in the ma.32 treatment trial. (participation in the ma.32 qol study is permitted but not required.)

the patient must not have started taking ma.32 study therapy.

the patient must have completed primary breast radiation therapy at least two weeks prior to enrollment in ma.32.f.

ma.32 study therapy has been initiated.

currently receiving radiation therapy or additional radiation therapy is planned for initiation after starting ma.32 study therapy.